| Dr Mark J Greenbaum, DPM | |
|
1835 Savoy Dr Ste 200, Atlanta, GA 30341-1073 | |
| (770) 279-2900 | |
| (770) 279-0351 |
| Full Name | Dr Mark J Greenbaum |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 36 Years |
| Location | 1835 Savoy Dr Ste 200, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750335428 | NPI | - | NPPES |
| 00412068A | Medicaid | GA | |
| 480020017 | Other | GA | RR MEDICARE |
| 00412068C | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | POD000611 (Georgia) | Primary |
| Provider Name | Mark J Greenbaum Dpm Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1174713796 PECOS PAC ID: 7517955370 Enrollment ID: O20040503000409 |
News Archive
Los Robles Health System is leading the way in neurovascular clinical trials enrolling the first patient in the nation in STEM, the Squid trial for the treatment of chronic subdural hematoma (cSDH).
A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.
Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.
Relapse is the most painful and expensive feature of drug addiction-even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after treatment.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark J Greenbaum, DPM 1835 Savoy Dr Ste 200, Atlanta, GA 30341-1073 Ph: (770) 279-2900 | Dr Mark J Greenbaum, DPM 1835 Savoy Dr Ste 200, Atlanta, GA 30341-1073 Ph: (770) 279-2900 |
News Archive
Los Robles Health System is leading the way in neurovascular clinical trials enrolling the first patient in the nation in STEM, the Squid trial for the treatment of chronic subdural hematoma (cSDH).
A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.
Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.
Relapse is the most painful and expensive feature of drug addiction-even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after treatment.
› Verified 4 days ago
Ayanda Dube, Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1364 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-727-5658 | |
Dr. Barbara S. Schlefman, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2789 Joel Pl, Atlanta, GA 30360 Phone: 770-604-3803 | |
Primera Foot & Ankle Centers Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1150 Hammond Dr Bldg E, Suite 600, Atlanta, GA 30328 Phone: 678-395-3628 Fax: 678-691-5164 | |
Dr. Frank Andrew Sinkoe, OPM DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 1935 Cliff Valley Way Ne, 118, Atlanta, GA 30329 Phone: 404-329-5050 Fax: 404-329-5005 | |
Diabetic Foot Care Specialist Of Georgia Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 238 Walker St Sw, Unit #12, Atlanta, GA 30313 Phone: 404-759-6755 Fax: 334-271-3768 | |
Margo Angela Jimenez, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2295 Parklake Dr Ne Ste 150, Atlanta, GA 30345 Phone: 770-938-5974 Fax: 770-939-4450 | |
Mystic Medical, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 5555 Glenridge Connector, Suite 200, Atlanta, GA 30342 Phone: 404-351-0055 |